Physician profile
Brandy Eason
NPI 1548629199
$12,588.34
in general payments reported to CMS, 2019-2025
36 companies · $2,765 in 2025
The $2,765 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,784 · 2022: $2,354 · 2023: $2,490 · 2024: $3,195 · 2025: $2,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,290 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,290.35 |
| Education | $159.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,037.80 | 2021-2025 | |
| Janssen Biotech, INC. | $1,356.21 | 2022-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,171.07 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Enterra Medical, INC. | $526.41 | 2022-2024 | |
| Gilead Sciences, INC. | $498.77 | 2022-2025 | Epclusa |
| Ironwood Pharmaceuticals, INC | $464.11 | 2021-2024 | Linzess |
| Aimmune Therapeutics, INC. | $464.00 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $446.85 | 2022-2025 | Dupixent |
| Pfizer INC. | $429.67 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $364.43 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $353.89 | 2021-2024 | Gattex, Eohilia |
| Intercept Pharmaceuticals, INC. | $270.31 | 2021-2025 | Ocaliva |
| Ardelyx, INC. | $269.64 | 2022-2023 | Ibsrela |
| Madrigal Pharmaceuticals | $253.27 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $250.26 | 2021-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $214.51 | 2021-2023 | Dificid |
| Qol Medical, LLC | $192.08 | 2022-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $176.25 | 2024-2025 | Omvoh, Zepbound |
| Ipsen Biopharmaceuticals, INC | $163.05 | 2025 | Iqirvo, Bylvay |
| Janssen Scientific Affairs, LLC | $138.33 | 2022-2025 | Tremfya, Stelara |
| Ferring Pharmaceuticals INC. | $87.52 | 2021-2023 | Rebyota |
| Vivus LLC | $65.89 | 2024-2025 | Pancreaze, Qsymia |
| Redhill Biopharma INC. | $55.79 | 2021 | |
| Medtronic, INC. | $45.09 | 2021-2022 | |
| Genzyme Corporation | $39.10 | 2023 | |
| Novo Nordisk INC | $34.66 | 2025 | Wegovy |
| Ucb, INC. | $28.54 | 2021 | |
| Shield Therapeutics INC | $28.32 | 2025 | |
| Axonics, INC. | $26.37 | 2021-2022 | |
| Braintree Laboratories, INC. | $25.66 | 2021 | |
| Endogastric Solutions, INC | $24.33 | 2024 | Esophyx |
| Phadia US INC. | $19.49 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.74 | 2023 | Cyltezo |
| Amgen INC. | $16.20 | 2021 | |
| Exact Sciences Corporation | $15.94 | 2023 | Cologuard Collection Kit |
| Celgene Corporation | $15.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Eason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.